PubMed Health⌕ Search

Biomedical subjects

I B Petersen

Publications and source records attributed to I B Petersen.

6 recordsLinked to original sources

Clinical evaluation of long-term treatment with levo-norgestrel and testosterone enanthate in normal men.

Thirteen healthy men (25-35 years) with proven fertility were scheduled for long-term treatment (> 12 months) with levo-norgestrel (500 micrograms daily) and testosterone enanthate (200 mg monthly). The volunteers were regularly investigated prior to, during and after treatment. Seven volunteers withdrew from medication after 1 to 12 months of treatment; three due to psychological side effects, one because of stiffness of a finger joint, two for personal reasons and one for unspecified reasons. Sperm counts were significantly decreased during treatment and in 7 volunteers the sperm counts were < 5 x 10(6)/ml. However, two of these volunteers exhibited a breakthrough in sperm counts after 12 and 13 months of a 16-month treatment period. Serum testosterone, serum LH and serum FSH were significantly decreased during treatment, but returned, as did sperm counts, to normal levels after withdrawal of treatment. No rebound effect was seen. Potency and libido remained unchanged. No toxicological side effects were observed and finally no consistent changes were seen in blood coagulation parameters.

Adult↗

Clinical trial with levo-norgestrel and testosterone oenanthate for male fertility control.

Two groups of six men took levo-norgestrel (250 or 500 microgram daily) by mouth and testosterone oenanthate (200 mg monthly, intramuscurlarly) for six months. A three months placebo period preceded the medication which was followed by a recovery phase of 6-10 months. Two volunteers withdrew due to side effects. The five men taking the low doses of levo-norgestrel (250 microgram) exhibited a reduction in sperm count, but not to azoospermia. The high dose of levo-norgestrel (500 microgram) was more effective, sperm count was reduced to < 6 X 10(6)/ml in 3 of 5 volunteers and to < 17 X 10(6)/ml in the remainder. s-Testosterone, LH and FSH were decreased by the treatment. The men had no toxicological side effects or changes in libido and potency. During the recovery period sperm counts, sperm morphology, s-testosterone, LH and FSH returned to normal levels.

Adult↗

Serum-testosterone during oral administration of testosterone in hypogonadal men and transsexual women.

Testosterone tablets of crystal size 2-5 micrometer were administered orally for 10 dags to 3 human subjects with low endogenous serum testosterone (se-T) levels. Fifty mg testosterone increased se-T slightly, while one daily dose of 200 mg maintained the se-T level within normal range for men for more than 12h. No cumulative effect was seen. Seven further subjects with low androgen production ingested 100 or 200 mg testosterone of crystal size 125-400 micrometer. Blood samples were taken frequently during the 24 h period following administration of the testosterone and se-T levels determined. Testosterone levels in serum increased in 6 patients and was maintained within the normal male range for 5-7 h. In one subject a slight but significant increase in se-T was observed although the level did not reach the normal male range. Although it has been shown that it is possible to use orally administered testosterone to maintain se-T levels in the normal male range, the convenience to the patient must be balanced against the cost and possible side effects of the large doses required.

Administration, Oral↗